---
title: 'Hematopoietic stem cell transplantation for DLBCL: a report from the European
  Society for Blood and Marrow Transplantation on more than 40,000 patients over 32
  years'
date: '2024-07-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38969655/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240706182815&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation
  (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma
  (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies.
  We examined the transplantation trends and outcomes for DLBCL patients undergoing
  auto-/allo-HSCT between 1990 and 2021 reported to EBMT. Over this period, 41,148
  patients underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw
  a ...
disable_comments: true
---
Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies. We examined the transplantation trends and outcomes for DLBCL patients undergoing auto-/allo-HSCT between 1990 and 2021 reported to EBMT. Over this period, 41,148 patients underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw a ...